These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use. Mizuno H, Sekine A, Suwabe T, Ikuma D, Yamanouchi M, Hasegawa E, Sawa N, Ubara Y, Hoshino J. PLoS One; 2022; 17(2):e0264065. PubMed ID: 35176098 [Abstract] [Full Text] [Related]
25. Carbohydrate antigen 19-9 is significantly elevated in autosomal dominant polycystic kidney disease. Fukasawa H, Kaneko M, Niwa H, Yasuda H, Kumagai H, Furuya R. Nephrology (Carlton); 2018 Mar; 23(3):210-216. PubMed ID: 28024168 [Abstract] [Full Text] [Related]
26. Demographic and clinical characteristics of children with autosomal dominant polycystic kidney disease: a single center experience. Kasap Demir B, Mutlubaş F, Soyaltın E, Alparslan C, Arya M, Alaygut D, Arslansoyu Çamlar S, Berdeli A, Yavaşcan Ö. Turk J Med Sci; 2021 Apr 30; 51(2):772-777. PubMed ID: 33315352 [Abstract] [Full Text] [Related]
27. Spleen phenotype in autosomal dominant polycystic kidney disease. Yin X, Prince WK, Blumenfeld JD, Zhang W, Donahue S, Bobb WO, Rennert H, Askin G, Barash I, Prince MR. Clin Radiol; 2019 Dec 30; 74(12):975.e17-975.e24. PubMed ID: 31563290 [Abstract] [Full Text] [Related]
35. Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data. Gevers TJ, Inthout J, Caroli A, Ruggenenti P, Hogan MC, Torres VE, Nevens F, Drenth JP. Gastroenterology; 2013 Aug 30; 145(2):357-65.e1-2. PubMed ID: 23665274 [Abstract] [Full Text] [Related]
36. Liver cysts in Congolese patients with autosomal dominant polycystic kidney disease follow a family pattern. Assounga AG, Yacoubou Y, Makosso E, Ibara JR, Gombet T. S Afr Med J; 2003 Jul 30; 93(7):542-4. PubMed ID: 12939930 [Abstract] [Full Text] [Related]